1293. The Next Step in PrEP: Evaluating Outcomes of a Pharmacist-Run HIV Pre-Exposure Prophylaxis (PrEP) Clinic
Session: Poster Abstract Session: HIV: Prevention
Friday, October 5, 2018
Room: S Poster Hall

Background: PrEP has been proven as an effective option for preventing the transmission of HIV; however, there are limited numbers of providers willing to prescribe PrEP.  Pharmacists are an underutilized resource that are able to provide PrEP services in many states.  In Albuquerque, New Mexico, one of the nation’s first pharmacy-run HIV PrEP clinics was established in July 2015. The objective of this study was to describe the outcomes of an alternative model for HIV prevention.

Methods: The electronic medical record was used to identify and retrospectively review patients of the PrEP clinic from 07/2015-07/2017.  Pertinent information including: risk factors for HIV acquisition, sexually transmitted infections (STIs) history, laboratory and medication-related data was captured. Data on partner HIV status and HAART regimen was collected when available.  Adherence was evaluated by self-reported missed doses and the compliance rate was calculated from the patient’s medication fill history.  Descriptive statistics was performed using SPSS.

Results: The 1st PrEP appointment was attended by 136 patients during study period. Baseline demographics are reported in Table 1. Two patients tested positive for HIV at baseline. PrEP was started in 127 patients with tenofovir/emtricitabine (TDF/FTC). There were no HIV seroconversions among those who started PrEP. Only one patient discontinued due to side effects. No significant elevation in Scr was noted over time. Overall, patients demonstrated a high adherence rate with an average of <1 missed doses per month and a median compliance rate of 0.99.

Conclusion: A pharmacist run PrEP clinic is an alternative model to increase patient access to PrEP. TDF/FTC was provided to high-risk individuals and well-tolerated. Providers were able to promote high level of adherence.  

Table 1. Baseline Demographics

N=136

Average Age

34 years [20-73]

Males (self-identified)

117 (86.1%)

Race

n (%)

Hispanic

White

American Indian Alaskan Native

Black/African American

Other

Unknown

57 (42)

53 (39)

13 (10)

5 (4)

4 (3)

4 (3)

HIV Risk Factor

n (%)

Total High Risk MSM

HIRI-MSM score (mean ± SD)

High Risk Transgender

Sero-discordant couples

Transactional Sex

Drug Use

History of STI

Previous PEP use

117 (86)

17.7 ± 7.54

10 (7)

40 (29)

3 (2)

5 (4)

12 (9)

2 (2)

Keenan Ryan, PharmD, PhC1, Jessica Lewis, BS Biology/Psychology2, Daniel Sanchez, BS3, Beverly Anderson, BA3 and Renee-Claude Mercier, PharmD4, (1)University of New Mexico Health Sciences Center, Albuquerque, NM, (2)College of Pharmacy, University of New Mexico, Albuquerque, NM, (3)University of New Mexico, Albquerque, NM, (4)University of New Mexico College of Pharmacy, University of New Mexico College of Pharmacy, Albquerque, NM

Disclosures:

K. Ryan, None

J. Lewis, None

D. Sanchez, None

B. Anderson, None

R. C. Mercier, None

See more of: HIV: Prevention
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.